Literature DB >> 21311103

Framingham risk score and early markers of atherosclerosis in a cohort of adults infected with HIV.

E Liana Falcone1, Alexandra Mangili, Sally Skinner, Ahsan Alam, Joseph F Polak, Christine A Wanke.   

Abstract

BACKGROUND: The utility of the Framingham risk score among individuals infected with HIV is poorly understood. We examined the association of Framingham risk scores with surrogate markers of atherosclerosis in a carefully characterized cohort of adults infected with HIV.
METHODS: We calculated Framingham risk scores and measured carotid intima-media thickness (c-IMT) and coronary artery calcium (CAC) scores in 334 participants from the Nutrition for Healthy Living study. Cardiovascular risk factors, c-IMT and CAC scores were assessed for each Framingham risk subgroup (low versus intermediate/high risk). We used adjusted and unadjusted linear and logistic regression to examine the association between clinical factors and Framingham risk group with c-IMT and CAC scores.
RESULTS: Patients with intermediate/high Framingham risk scores were more likely to have internal c-IMT ≥ 1.0 mm (26% versus 12%; P=0.003) and common c-IMT ≥ 0.8 mm (22% versus 5%; P < 0.001). These patients were also more likely to have detectable CAC (78% versus 48%; P < 0.001). Intermediate/high Framingham risk scores were significantly associated with internal c-IMT ≥ 1.0 mm (odds ratio 2.65 [95% confidence interval 1.37-5.13]) and common c-IMT ≥ 0.8 mm (odds ratio 5.24 [95% confidence interval 2.39-11.50]). Intermediate/high Framingham risk scores were also significantly associated with detectable CAC (odds ratio 3.84 [95% confidence interval 2.05-7.16]). The addition of HIV-related variables did not improve the accuracy of the Framingham risk score.
CONCLUSIONS: Our study shows that increased Framingham risk scores are associated with abnormal early and late surrogate markers of atherosclerosis in adults infected with HIV, and might predict the risk of cardiovascular complications in this population.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21311103     DOI: 10.3851/IMP1682

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  13 in total

1.  HIV and coronary artery calcium score: comparison of the Hawaii Aging with HIV Cardiovascular Study and Multi-Ethnic Study of Atherosclerosis (MESA) cohorts.

Authors:  Dominic Chow; Rebekah Young; Nicole Valcour; Richard A Kronmal; Corey J Lum; Nisha I Parikh; Russell P Tracy; Matthew Budoff; Cecilia M Shikuma
Journal:  HIV Clin Trials       Date:  2015-06-03

2.  Cardiovascular risk-factor knowledge and risk perception among HIV-infected adults.

Authors:  Patricia A Cioe; Sybil L Crawford; Michael D Stein
Journal:  J Assoc Nurses AIDS Care       Date:  2013-09-24       Impact factor: 1.354

3.  Long-term predictive value of the Framingham Risk Score for Stroke in HIV-positive vs HIV-negative men.

Authors:  Farrah J Mateen; Wendy S Post; Ned Sacktor; Alison G Abraham; James T Becker; Bryan R Smith; Roger Detels; Eileen Martin; John P Phair; Russell T Shinohara
Journal:  Neurology       Date:  2013-11-08       Impact factor: 9.910

4.  Risk of cardiovascular disease in HIV, hepatitis C, or HIV/hepatitis C patients compared to the general population.

Authors:  L Kakinami; R C Block; M J Adams; S E Cohn; B Maliakkal; S G Fisher
Journal:  Int J Clin Pract       Date:  2013-01       Impact factor: 2.503

5.  Cardiovascular Risk in HIV-Infected and Uninfected Postmenopausal Minority Women: Use of the Framingham Risk Score.

Authors:  Yamnia I Cortés; Nancy Reame; Cosmina Zeana; Haomiao Jia; David C Ferris; Elizabeth Shane; Michael T Yin
Journal:  J Womens Health (Larchmt)       Date:  2016-09-09       Impact factor: 2.681

6.  A possible role for CCR5 in the progression of atherosclerosis in HIV-infected patients: a cross-sectional study.

Authors:  Laura Fernández-Sender; Carlos Alonso-Villaverde; Anna Rull; Esther Rodríguez-Gallego; Marta Riera-Borrull; Anna Hernández-Aguilera; Jordi Camps; Raúl Beltrán-Debón; Gerard Aragonès; Javier A Menendez; Jorge Joven
Journal:  AIDS Res Ther       Date:  2013-05-09       Impact factor: 2.250

7.  Lopinavir/ritonavir versus darunavir plus ritonavir for HIV infection: a cost-effectiveness analysis for the United States.

Authors:  Kit N Simpson; Pamela P Pei; Jörgen Möller; Robert W Baran; Birgitta Dietz; William Woodward; Kristen Migliaccio-Walle; J Jaime Caro
Journal:  Pharmacoeconomics       Date:  2013-05       Impact factor: 4.558

8.  Current Efavirenz (EFV) or ritonavir-boosted lopinavir (LPV/r) use correlates with elevate markers of atherosclerosis in HIV-infected subjects in Addis Ababa, Ethiopia.

Authors:  Rudolph L Gleason; Alexander W Caulk; Daniel Seifu; Ivana Parker; Brani Vidakovic; Helena Getenet; Getachew Assefa; Wondwossen Amogne
Journal:  PLoS One       Date:  2015-04-27       Impact factor: 3.240

Review 9.  A review of cardiovascular and renal function monitoring: a consideration of older adults with HIV.

Authors:  Clark D Kebodeaux; Alexandria Garavaglia Wilson; Daron L Smith; Scott Martin Vouri
Journal:  HIV AIDS (Auckl)       Date:  2013-09-16

10.  Mind the gap: difference between Framingham heart age and real age increases with age in HIV-positive individuals-a clinical cohort study.

Authors:  Teri-Louise Davies; Mark Gompels; Sarah Johnston; Begoña Bovill; Margaret T May
Journal:  BMJ Open       Date:  2013-10-25       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.